Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KNK-ID-101
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**KNK-ID-101** is an off-the-shelf natural killer (NK) cell therapy developed by Kiadis Pharma using proprietary PM21 particle technology and Universal Donor platform to enable large-scale manufacturing of expanded and activated NK cells from unique universal donors. It leverages enhanced NK cell anti-viral properties demonstrated in prior trials against CMV and BKV infections, positioning it as a post-exposure pre-emptive therapy for high-risk COVID-19 patients by repairing deficient NK cell function, eliminating SARS-CoV-2 infected cells, and synergizing with antibodies and vaccines without exacerbating inflammation.[3][5][7][9]
- Other names
- Kiadis NK cellsK-NK cells
Beyond the preview
Go deeper on KNK-ID-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KNK-ID-101.